NeurAxis (NRXS) Q2 2024 earnings summary

Executive summary

• Achieved significant milestones in insurance policy coverage for IB-Stim, expanding to 22.5 million lives with a major payer covering 12 million more starting October 2024, setting the stage for accelerated revenue growth and a clear path to profitability in 2025.

• Academic society NASPGHAN released a systematic review granting the technology the highest grade certainty, expected to drive guideline publication and further insurance adoption.

• Commercialization of the RED device is on track for late 2024, with FDA submission completed and strong reimbursement prospects; FDA clearance expected in Q4 2024.

• Focused on neuromodulation therapies for pediatric chronic conditions, with IB-Stim as the primary FDA-cleared product for functional abdominal pain associated with IBS in children.

• Auditors expressed substantial doubt about the company's ability to continue as a going concern.

Financial highlights

• Q2 2024 revenue was $611,500–$612,000, down 5.3% year-over-year, but a smaller decline than prior quarters.

• Gross profit for Q2 2024 was $538,000, with an 88% gross margin, slightly down from 89.5% in Q2 2023 due to discounted sales through financial assistance.

• Operating loss for Q2 2024 was $2.2 million, up from $1.1 million in Q2 2023, driven by higher payroll, public company costs, advertising, and $435,000 in nonrecurring severance and consulting.

• Net loss for Q2 2024 was $2.92–$2.9 million, up 30.5% year-over-year, impacted by higher G&A and non-cash settlements.

• Cash on hand at June 30, 2024 was $1.8 million, up from $51,000 a year prior, with $4.2 million in additional committed capital; short-term debt totaled $4.8 million.

Outlook and guidance

• Profitability expected in Q1 2025, with no change to prior guidance; however, existing cash is expected to meet operating needs only through the end of 2024.

• Revenue growth anticipated to accelerate in the second half of 2024 and into 2025, driven by expanded insurance coverage and RED commercialization.

• Insurance coverage expected to double to 50 million lives in 2H24, supporting revenue growth.

• Cash burn projected at $400,000–$500,000 per month, with a 12-month runway based on current liquidity and committed capital.

• Future capital needs depend on insurance adoption, R&D, and regulatory milestones.